Spinal muscular atrophy is a disease that causes muscle weakness which mostly appears in newborn children. Spinal muscular atrophy disease incidence of approximately 1 in 10,000 newborns and a prevalence of approximately 1 to 2 per 100,000 persons, globally. Spinal muscular atrophy is basically 4 types – Type 1, Type 2, Type 3 and Type 4. Most patients suffers with Spinal muscular atrophy type 1. According to Renub Research Global Spinal Muscular Atrophy Market is anticipated to grow at a CAGR of 14.29 percent in future. This double digit growth rate will happen due to expected launch of new drugs, better reimbursement options and decline in drugs prices.
Request a free sample copy of the report: https://www.renub.com/contactus.php
Spinal Muscular Atrophy (SMA) type 1 develop in less than 6 months of new born children in which patients are not in position to sit in their lifetime and normally they die within 6 months. In spinal muscular atrophy type 2, patients can sit but cannot walk. Type 2 is developed between 6-18 months of the new born children. Spinal muscular atrophy Type 3 patients can sit and walk and it developed when children age is less than 18 months. Spinal muscular atrophy Type 4 can develop during the adulthood.
Renub Research report titled “Spinal Muscular Atrophy Market Global Forecast by Countries (United States, United Kingdom, France, Germany, Spain, Italy & Japan), Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070), Companies (Biogen Inc., Roche AG, Novartis AG, Cytokinetics Inc)” studies the global spinal muscular atrophy market and provides an all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.
Spinal Muscular Atrophy Market New Drugs are expected to launch in recent years
At present only Biogen’s Spinraza is approved for the treatment of spinal muscular atrophy patients in the various parts of the globe such as United States, Europe, and Japan etc. Other companies are also working for new drugs development and they hope to enter in the market place very soon as their drugs are in Phase III clinical trials.
By Country – Market Segmentation
Spinal muscular atrophy market by country has been segmented into United States, United Kingdom, France, Germany, Spain, Italy and Japan. United States is a leading market place due to increasing number of treated Patients, favorable reimbursement policies and increase in healthcare expenditure.
By Total & Treated Patients – Population Segmentation
Spinal muscular atrophy Total & Treated Patients by country has been segmented into United States, United Kingdom, France, Germany, Spain, Italy and Japan. United States is dominating in the treated SMA patients globally.
By Drugs – Market Segmentation
The report by Renub Research studies the spinal muscular atrophy six drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070) details with present and estimated global sales.
The Report has been analyzed from 9 Major Viewpoints
1. Global Spinal Muscular Atrophy Market (Present & Forecast)2. Global Spinal Muscular Atrophy Market Share, Patients Share, Treated Patients Share (Present & Forecast)3. Country Spinal Muscular Atrophy Market (Present & Forecast)4. Country Spinal Muscular Atrophy Patients Population (Present & Forecast)5. Country Spinal Muscular Atrophy Treated Patients Population (Present & Forecast)6. Spinal Muscular Atrophy Drugs Sales (Present & Forecast)7. Global – Clinical Study on Spinal Muscular Atrophy & Drugs Pipeline 8. Growth Drivers and Challenges9. Key Spinal Muscular Atrophy Companies Initiatives and Financial Insight
Client can Purchase this Report in Sections from below link:
Access full Research: https://www.renub.com/spinal-muscular-atrophy-market-p.php
Country Covered in this Report
• United States• United Kingdom• France • Germany• Italy • Spain• Japan
Drugs Details Covered in this Report
• Spinraza• AVXS-101• CK2127107• RG7916• Olesoxime• LMI070
Company Covered in this Report
• Biogen Inc.• Roche AG• Novartis AG• Cytokinetics Inc
If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team at [email protected]
Browse Related Report:
Multiple Sclerosis Market
US Generic Drugs Market
Contact Us
Renub Research
Phone:+1-678-302-0700
Email: [email protected]
Key Topics Covered:
1. Introduction
1.1 Market Definition1.2 Currency Conversion
2. Research Methodology
3. Executive Summary
4. Global Spinal Muscular Atrophy Market and Patients Analysis
4.1 Spinal Muscular Atrophy Market4.2 Spinal Muscular Atrophy Patient Numbers4.3 Spinal Muscular Atrophy Treated Patient Number
5. Share Analysis – Global Spinal Muscular Atrophy
5.1 Country Market Share5.2 Patients Population Share5.3 Treated Patients Share
6. United States
6.1 Spinal Muscular Atrophy Market6.2 Spinal Muscular Atrophy Patient Numbers6.3 Spinal Muscular Atrophy Treated Patients
7. United Kingdom
7.1 Spinal Muscular Atrophy Market7.2 Spinal Muscular Atrophy Patient Numbers7.3 Spinal Muscular Atrophy Treated Patient Numbers
8. Germany
8.1 Spinal Muscular Atrophy Market8.2 Spinal Muscular Atrophy Patient Numbers8.3 Spinal Muscular Atrophy Treated Patients
9. Italy – Spinal Muscular Atrophy
9.1 Spinal Muscular Atrophy Market9.2 Spinal Muscular Atrophy Patient Numbers9.3 Spinal Muscular Atrophy Treated Patient Numbers
10. France – Spinal Muscular Atrophy
10.1 Spinal Muscular Atrophy Market10.2 Spinal Muscular Atrophy Patient Numbers10.3 Spinal Muscular Atrophy Treated Patient Numbers
11. Spain
11.1 Spinal Muscular Atrophy Market11.2 Spinal Muscular Atrophy Patient Numbers11.3 Spinal Muscular Atrophy Treated Patient Numbers
12. Japan
12.1 Spinal Muscular Atrophy Market12.2 Spinal Muscular Atrophy Patients12.3 Spinal Muscular Atrophy Treated Patient Numbers
13. Drugs Sales – Spinal Muscular Atrophy
13.1 Spinraza13.2 AVXS-10113.3 CK212710713.4 RG791613.5 Olesoxime13.6 LMI070
14. Spinal Muscular Atrophy Study Status Analysis
14.1 Spinal Muscular Atrophy Clinical Study14.2 Spinal Muscular Atrophy Drugs Development Pipeline
15. Growth Drivers
15.1 Increasing Funding for Research & Development15.2 Biogen Access Programs
16. Challenges
16.1 High Treatment Cost16.2 Common Side Effects
17. Biogen Inc.
17.1 Business Overview17.2 Initiatives/Strategies17.3 Financial Insight
18. Novartis AG
18.1 Business Overview18.2 Initiatives/Strategies18.3 Financial Insight
19. Roche Holding AG
19.1 Business Overview19.2 Initiatives/Strategies19.3 Financial Insight
20. Cytokinetics, Inc.
20.1 Business Overview20.2 Initiatives/Strategies20.3 Financial Insight
Media ContactCompany Name: Renub ResearchContact Person: Rajat GuptaEmail: Send EmailPhone: 6783020700Address:225 Kristie Ln City: RoswellState: GACountry: United StatesWebsite: www.renub.com/life-science-1-c.php
